Two mushrooms. Two completely different pharmacological stories.
Psilocybin mushrooms and amanita muscaria are both called "magic mushrooms" in casual conversation, but that label flattens a meaningful biological distinction. They don't work the same way, they don't feel the same way, and they're not in the same legal category in most of the United States. If you're trying to understand the difference, starting with the chemistry is the clearest path.
How muscimol works (GABA-A agonism)
The psychoactive compound in amanita muscaria is muscimol. It works by binding to GABA-A receptors, the same receptor class that benzodiazepines, barbiturates, and alcohol target. GABA is the brain's primary inhibitory neurotransmitter. When muscimol activates GABA-A receptors, it broadly suppresses neural firing across the brain.
What does that feel like? Users typically describe sedation, dreamlike or dissociative states, distorted sense of time, and unusual perceptual changes. In higher doses, the experience feels more like a vivid dream than a waking hallucination. Some describe a kind of weightlessness or body heaviness, and the boundary between sleep and wakefulness can blur.
This mechanism is inhibitory. The brain is being quieted, not stimulated.
One thing worth knowing: amanita muscaria also contains ibotenic acid, which converts to muscimol when the mushroom is dried and heated. Raw amanita carries a different and less predictable compound ratio. How the mushroom is prepared matters a lot.
How psilocybin works (5-HT2A agonism)
Psilocybin is a prodrug. The body converts it to psilocin, which binds primarily to 5-HT2A serotonin receptors, particularly in the cortex. This is a stimulatory mechanism, not inhibitory. 5-HT2A agonism in the prefrontal cortex disrupts the brain's default mode network. That system handles the baseline sense of self and how we filter sensory input.
The effects are dramatically different from muscimol. Psilocin tends to produce visual hallucinations, synesthesia, dissolution of ego boundaries, intense emotional responses, and a general amplification of sensory experience. The experience is active, not sedating.
Psilocybin has become the center of a substantial research wave. Studies out of Johns Hopkins, NYU, and Imperial College London have shown therapeutic potential for treatment-resistant depression, PTSD, and end-of-life anxiety. None of that clinical research has been replicated yet for muscimol.
Legal status: the gap that actually matters
This is where the difference between the two becomes practically important.
Psilocybin (and psilocin) are Schedule I substances under the federal Controlled Substances Act. Possession, sale, and distribution are federal crimes. A small number of states and municipalities have decriminalized psilocybin or created specific regulatory exceptions for therapeutic use, Oregon and Colorado being the most significant, but the baseline in the U.S. is federally illegal.
Amanita muscaria and muscimol are not scheduled under federal law. The mushroom itself is sold legally in most states. Louisiana is the notable exception, explicitly prohibiting amanita muscaria. A few other states have regulatory ambiguity. But in the overwhelming majority of the country, products containing amanita muscaria and muscimol can be sold commercially.
This legal gap is why the consumer market for amanita products has grown so quickly. Muscimol is not a workaround for psilocybin. It's a different compound with a different mechanism. But the legal distinction is real, and it matters for anyone who works in or buys from this category. To learn more about the legality breakdown by state, see our guide on muscimol gummies or our full mushroom gummies legality guide.
How the effects compare
Muscimol and psilocybin diverge most sharply when you look at what the actual experience is like.
With muscimol, onset runs 30 to 90 minutes depending on consumption method, and the experience typically lasts 4 to 8 hours, sometimes longer at higher doses. The character is sedating and dreamlike. Visual effects are present but tend toward "dream logic" rather than geometric patterns. Emotionally, the experience leans calm or inward. Dose sensitivity is high; small changes produce meaningfully different experiences.
With psilocybin, onset is typically 30 to 60 minutes, with a 4 to 6 hour duration. The character is stimulating and perceptually intense. Closed- and open-eye visuals, geometric patterns, and object distortion are common. Emotionally, it amplifies whatever state you bring into the experience, which is why set and setting matter so much. Dose sensitivity is equally high.
If you want a more complete picture of what an amanita experience is actually like, the what does amanita muscaria feel like article covers it in depth.
Safety: what each compound actually risks
Both require responsible use. Neither is without risk. But the risk profiles are different in ways that matter.
The primary risk with amanita muscaria is dosing imprecision, particularly with raw or inadequately prepared mushrooms. Ibotenic acid, the precursor compound, is neurotoxic at high doses. Drying and heating converts it to muscimol, but inconsistent preparation can leave variable ibotenic acid levels. Properly processed, standardized preparations carry lower risk than foraging and self-preparing wild mushrooms.
Muscimol interactions with other CNS depressants are also worth knowing: alcohol, benzodiazepines, and sleep aids all amplify sedation unpredictably in combination. There is no evidence of organ toxicity from muscimol at reasonable doses, and no documented deaths attributed to muscimol alone. For a consumer-focused breakdown, see our guide to mushroom gummy safety.
Psilocybin has an extremely low physiological toxicity profile. Johns Hopkins researchers have published that it ranks among the safest substances by physical harm metrics. The primary risks are psychological: challenging experiences, anxiety, and in rare cases, psychosis precipitation in people with a personal or family history of psychotic disorders. People with schizophrenia or bipolar I disorder are consistently flagged as contraindicated in clinical research.
How to think about this as a consumer
These two compounds are not interchangeable. Choosing between them is not a matter of preferring more or less intensity. They work through different receptor systems, feel different, carry different legal statuses, and have different risk profiles.
If you're interested in an amanita experience: understand the mechanism (GABA-A inhibition, sedating and dissociative), start with a low dose, use properly prepared products with verified muscimol content, and avoid mixing with other CNS depressants. The experience is more inward and dream-like than what most people picture when they hear "psychedelic."
If you're interested in psilocybin: the legal context is the first thing to understand. Where it's decriminalized or available through therapeutic programs, set, setting, and dose are the variables that matter most. The research on therapeutic applications is growing fast, but self-directed use carries the same need for respect as any high-intensity experience.
Neither is better. They're different compounds for different experiences. Treating them as equivalent misses what's actually interesting about each.
This article is educational only. Wunder does not make medical claims. Nothing here is medical advice. Always consult a healthcare provider before using any supplement, particularly if you take other medications.
